Enzymotec Ltd. (ENZY) 8.02 $ENZY
Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results
GlobeNewswire - Thu May 19, 6:30AM CDT
Reports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash Flow
ENZY: 8.02 (+0.03)
Enzymotec to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2016 on Thursday, May 19, 2016, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 8.02 (+0.03)
Update to Enzymotec Ltd. Shareholders Regarding Securities Class Action Lawsuit
Marketwired - Fri Apr 08, 3:05PM CDT
Co-Lead Counsel in the securities class action lawsuit pending in the District of New Jersey, which was filed in September 2014, provide this update to purchasers of Enzymotec Ltd.'s ("Enzymotec"
common stock during the Class Period between September 27, 2013 and August 4, 2014, inclusive, and also to purchasers of Enzymotec shares pursuant and/or traceable to the Company's initial public offering of its common stock (the "IPO" on or about September 27, 2013 and the Company's secondary public offering ("SPO" on or about February 27, 2014.
ENZY: 8.02 (+0.03)
Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT(R) Uses Promoting Development of Beneficial Gut Flora and Reducing Infant Crying Duration
GlobeNewswire - Tue Mar 29, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company has been granted two patents, one by the United States Patent Office and the second by the Chinese Patent and Trademark Office.
ENZY: 8.02 (+0.03)
InCog(TM), Enzymotec's Innovative Lipid Composition for Cognitive Functioning, Enhances Brain Development and Improves Survival in Preclinical Study
GlobeNewswire - Wed Mar 16, 7:30AM CDT
Enzymotec Ltd., (NASDAQ:ENZY) ("Company" or "Enzymotec" , a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that InCog, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study.
ENZY: 8.02 (+0.03)
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2015
GlobeNewswire - Tue Mar 08, 3:30PM CST
Enzymotec Ltd. (NASDAQ:ENZY) ("Company" , a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission ("SEC" . The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC's website at http://www.sec.gov/ as well as via the Company's investor relations website at http://ir.enzymotec.com/.
ENZY: 8.02 (+0.03)
Enzymotec (ENZY): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 9:13AM CST
Enzymotec Ltd. (ENZY) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
ENZY: 8.02 (+0.03)
Enzymotec Announces Positive Outcome in ICC Arbitration Award
GlobeNewswire - Tue Feb 02, 7:30AM CST
Arbitration tribunal rejects AAK's requests for declaratory relief in their entirety
ENZY: 8.02 (+0.03)
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31, 2019
GlobeNewswire - Mon Jan 04, 7:00AM CST
Enzymotec Ltd. (NASDAQ:ENZY) (the "Company" , a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, reports that neither it nor AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec's joint venture partner in Advanced Lipids AB, has issued a notice of termination of the joint venture agreement (the "JV Agreement" to the other party by the December 31, 2015 deadline that is specified under the terms of the JV Agreement. Hence, under its terms, the JV Agreement has been automatically extended until December 31, 2019.
ENZY: 8.02 (+0.03)
Enzymotec Granted Mexican Patent for INFAT(R) Uses Related to Promoting Intestinal Health
GlobeNewswire - Mon Dec 21, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that INFAT(R), the innovative ingredient that is marketed by Advanced Lipids, an AAK and Enzymotec joint venture, was granted a patent by the Mexican Patent Office for uses related to promoting intestinal health.
ENZY: 8.02 (+0.03)
Enzymotec's InCog(TM), an Innovative Lipid Composition for Cognitive Functioning, Approved as Novel Food in Europe
GlobeNewswire - Tue Dec 01, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that its InCog, an innovative lipid composition for cognitive functioning, received Novel Food approval in Europe for conventional food, food supplements and dietary food for special medical purposes.
ENZY: 8.02 (+0.03)
Why Enzymotec (ENZY) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Mon Nov 23, 7:58AM CST
Enzymotec is seeing solid activity on the earnings estimate revision front, and the stock has also started to move higher lately, adding 14.7% over the past four weeks
ENZY: 8.02 (+0.03)
Enzymotec Ltd. Reports Third Quarter 2015 Results
GlobeNewswire - Wed Nov 11, 6:30AM CST
Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
ENZY: 8.02 (+0.03)
Enzymotec to Host a VAYA Pharma Analyst and Investor Day in New York City on November 19, 2015
GlobeNewswire - Tue Nov 10, 7:30AM CST
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that the Company will host a VAYA Pharma Analyst and Investor Day at Four Times Square in New York City on November 19, 2015, beginning at 12pm ET.
ENZY: 8.02 (+0.03)
Retrospective Analysis of the Effects of Enzymotec's Vayarin(R) Showed Significant Improvement of Emotional Status and Sleep Quality in ADHD Patients With Sleep Disturbances
GlobeNewswire - Mon Nov 09, 8:00AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enyzmotec" or the "Company" , a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that a poster entitled "ANALYZING THE EFFECT OF VAYARIN(R) ON EMOTIONAL REGULATION AND SLEEP QUALITY IN ADHD PATIENTS SUFFERING FROM SLEEP DISTURBANCES" was presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd annual meeting by Dr. Arnold Mech, Medical Director and Head of The Mech Center Outpatient and Research, Sleep Centers of Texas. The poster presentation outlined the results of a retrospective analysis that evaluated the effect of Vayarin(R) on emotional regulation and sleep quality in ADHD patients suffering from sleep disturbances.
ENZY: 8.02 (+0.03)
Enzymotec to Report Third Quarter 2015 Financial Results
GlobeNewswire - Wed Oct 28, 3:05PM CDT
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2015 on Wednesday, November 11, 2015, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 8.02 (+0.03)
Enzymotec Ltd. Granted a New US Patent for Vayacog(R) in Pre-Dementia
GlobeNewswire - Wed Oct 28, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today it was granted a new patent by the United States Patent and Trademark Office for Vayacog(R), a proprietary prescription medical food for the dietary management of lipid imbalances associated with early memory impairment.
ENZY: 8.02 (+0.03)
Medtronic Next-Gen superDimension System to Aid Lung Cancer
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:20PM CDT
Medtronic's (MDT) superDimension navigation system is used in conjunction with GenCut core biopsy system to detect lung cancer, using the minimally invasive ENB approach.
ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), ENZY: 8.02 (+0.03), NUVA: 58.98 (-1.03)
Cardiovascular Systems Down on Bleak Q1 Preliminary Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:15PM CDT
Cardiovascular Systems' (CSII) preliminary fiscal first quarter results fell short of the Zacks Consensus Estimate on both the top and bottom-line fronts.
ICUI: 107.33 (-0.80), CSII: 18.36 (+0.41), ENZY: 8.02 (+0.03), NUVA: 58.98 (-1.03)
Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results
GlobeNewswire - Thu May 19, 6:30AM CDT
Reports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash Flow
ENZY: 8.02 (+0.03)
Enzymotec to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2016 on Thursday, May 19, 2016, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 8.02 (+0.03)
Update to Enzymotec Ltd. Shareholders Regarding Securities Class Action Lawsuit
Marketwired - Fri Apr 08, 3:05PM CDT
Co-Lead Counsel in the securities class action lawsuit pending in the District of New Jersey, which was filed in September 2014, provide this update to purchasers of Enzymotec Ltd.'s ("Enzymotec"
common stock during the Class Period between September 27, 2013 and August 4, 2014, inclusive, and also to purchasers of Enzymotec shares pursuant and/or traceable to the Company's initial public offering of its common stock (the "IPO" on or about September 27, 2013 and the Company's secondary public offering ("SPO" on or about February 27, 2014. ENZY: 8.02 (+0.03)
Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT(R) Uses Promoting Development of Beneficial Gut Flora and Reducing Infant Crying Duration
GlobeNewswire - Tue Mar 29, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that the Company has been granted two patents, one by the United States Patent Office and the second by the Chinese Patent and Trademark Office.
ENZY: 8.02 (+0.03)
InCog(TM), Enzymotec's Innovative Lipid Composition for Cognitive Functioning, Enhances Brain Development and Improves Survival in Preclinical Study
GlobeNewswire - Wed Mar 16, 7:30AM CDT
Enzymotec Ltd., (NASDAQ:ENZY) ("Company" or "Enzymotec"
, a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that InCog, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. ENZY: 8.02 (+0.03)
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2015
GlobeNewswire - Tue Mar 08, 3:30PM CST
Enzymotec Ltd. (NASDAQ:ENZY) ("Company"
, a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2015 with the U.S. Securities and Exchange Commission ("SEC" . The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC's website at http://www.sec.gov/ as well as via the Company's investor relations website at http://ir.enzymotec.com/. ENZY: 8.02 (+0.03)
Enzymotec (ENZY): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 9:13AM CST
Enzymotec Ltd. (ENZY) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
ENZY: 8.02 (+0.03)
Enzymotec Announces Positive Outcome in ICC Arbitration Award
GlobeNewswire - Tue Feb 02, 7:30AM CST
Arbitration tribunal rejects AAK's requests for declaratory relief in their entirety
ENZY: 8.02 (+0.03)
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31, 2019
GlobeNewswire - Mon Jan 04, 7:00AM CST
Enzymotec Ltd. (NASDAQ:ENZY) (the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, reports that neither it nor AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec's joint venture partner in Advanced Lipids AB, has issued a notice of termination of the joint venture agreement (the "JV Agreement" to the other party by the December 31, 2015 deadline that is specified under the terms of the JV Agreement. Hence, under its terms, the JV Agreement has been automatically extended until December 31, 2019. ENZY: 8.02 (+0.03)
Enzymotec Granted Mexican Patent for INFAT(R) Uses Related to Promoting Intestinal Health
GlobeNewswire - Mon Dec 21, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that INFAT(R), the innovative ingredient that is marketed by Advanced Lipids, an AAK and Enzymotec joint venture, was granted a patent by the Mexican Patent Office for uses related to promoting intestinal health.
ENZY: 8.02 (+0.03)
Enzymotec's InCog(TM), an Innovative Lipid Composition for Cognitive Functioning, Approved as Novel Food in Europe
GlobeNewswire - Tue Dec 01, 7:30AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today that its InCog, an innovative lipid composition for cognitive functioning, received Novel Food approval in Europe for conventional food, food supplements and dietary food for special medical purposes.
ENZY: 8.02 (+0.03)
Why Enzymotec (ENZY) Could Be Positioned for a Surge?
Zacks Equity Research - Zacks Investment Research - Mon Nov 23, 7:58AM CST
Enzymotec is seeing solid activity on the earnings estimate revision front, and the stock has also started to move higher lately, adding 14.7% over the past four weeks
ENZY: 8.02 (+0.03)
Enzymotec Ltd. Reports Third Quarter 2015 Results
GlobeNewswire - Wed Nov 11, 6:30AM CST
Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow
ENZY: 8.02 (+0.03)
Enzymotec to Host a VAYA Pharma Analyst and Investor Day in New York City on November 19, 2015
GlobeNewswire - Tue Nov 10, 7:30AM CST
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that the Company will host a VAYA Pharma Analyst and Investor Day at Four Times Square in New York City on November 19, 2015, beginning at 12pm ET.
ENZY: 8.02 (+0.03)
Retrospective Analysis of the Effects of Enzymotec's Vayarin(R) Showed Significant Improvement of Emotional Status and Sleep Quality in ADHD Patients With Sleep Disturbances
GlobeNewswire - Mon Nov 09, 8:00AM CST
Enzymotec Ltd. (Nasdaq:ENZY) ("Enyzmotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that a poster entitled "ANALYZING THE EFFECT OF VAYARIN(R) ON EMOTIONAL REGULATION AND SLEEP QUALITY IN ADHD PATIENTS SUFFERING FROM SLEEP DISTURBANCES" was presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd annual meeting by Dr. Arnold Mech, Medical Director and Head of The Mech Center Outpatient and Research, Sleep Centers of Texas. The poster presentation outlined the results of a retrospective analysis that evaluated the effect of Vayarin(R) on emotional regulation and sleep quality in ADHD patients suffering from sleep disturbances. ENZY: 8.02 (+0.03)
Enzymotec to Report Third Quarter 2015 Financial Results
GlobeNewswire - Wed Oct 28, 3:05PM CDT
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2015 on Wednesday, November 11, 2015, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
ENZY: 8.02 (+0.03)
Enzymotec Ltd. Granted a New US Patent for Vayacog(R) in Pre-Dementia
GlobeNewswire - Wed Oct 28, 7:30AM CDT
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, announced today it was granted a new patent by the United States Patent and Trademark Office for Vayacog(R), a proprietary prescription medical food for the dietary management of lipid imbalances associated with early memory impairment.
ENZY: 8.02 (+0.03)
Medtronic Next-Gen superDimension System to Aid Lung Cancer
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:20PM CDT
Medtronic's (MDT) superDimension navigation system is used in conjunction with GenCut core biopsy system to detect lung cancer, using the minimally invasive ENB approach.
ICUI: 107.33 (-0.80), MDT: 85.70 (-0.08), ENZY: 8.02 (+0.03), NUVA: 58.98 (-1.03)
Cardiovascular Systems Down on Bleak Q1 Preliminary Results
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:15PM CDT
Cardiovascular Systems' (CSII) preliminary fiscal first quarter results fell short of the Zacks Consensus Estimate on both the top and bottom-line fronts.
ICUI: 107.33 (-0.80), CSII: 18.36 (+0.41), ENZY: 8.02 (+0.03), NUVA: 58.98 (-1.03)
